Adjuvant mFOLFOX6 +/- Cetuximab in Patients With KRAS Mutant Resected Stage III Colon Cancer: NCCTG Intergroup Phase III Trial N0147.
- Citation:
- J Clin Oncol vol 28 (15s) abstr 3508
- Meeting Instance:
- ASCO 2010
- Year:
- 2010
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 477
- Pharmas:
- Grants:
- Corr. Author:
- Authors:
- R. Goldberg D. Sargent S. Thibodeau M. Mahoney A. Shields E. Chan S. Gill M. Kahlenberg S. Nair S. Alberts
- Networks:
- Study
- NCCTG-N0147
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: